Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Snap Inc (SNAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Snap Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Snap Inc trades at $4.57 (market cap $7.71B). The key difference: Snap Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | SNAP | |
|---|---|---|
Market Cap | $4.49B | $7.71B |
Sector | Health | Media |
52-Week High | $28.06 | $10.35 |
52-Week Low | $20.06 | $3.93 |
Enterprise Value | $3.69B | $9.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Snap Inc. (SNAP) trades at $4.65, down 4.12% on the day, reflecting investor concerns over its recent launch of high-priced AR glasses. The stock shows a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, revenue grew to $5.93 billion in 2025, yet the company remains unprofitable with a net loss of $460 million. Analyst sentiment is cautious, with a consensus price target of $7.22 but a majority hold rating.
Snap's outlook hinges on monetizing its augmented reality initiatives and achieving sustained user growth, but execution risks and competitive pressures from larger peers like Meta pose significant challenges. The stock offers speculative upside if new hardware gains traction, yet persistent losses and regulatory scrutiny over social media safety present substantial downside risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
